电力设备 行业周报 电网投资同比高增，储能展新品频现 行业评级：增持 报告日期： 2025-04-14 行业指数与沪深 300 走势比较 -30% -20% -10% 0% 10% 20% 30% 04-11 05-11 06-11 07-11 08-11 09-11 10-11 11-11 12-11 01-11 02-11 03-11 04-11 电力设备 沪深300 分析师：张志邦 执业证书号：S0010523120004 邮箱： zhangzhibang@hazq.com 分析师：刘千琳 执业证书号：S0010524050002 邮箱： liuqianlin@hazq.com 分析师：郑洋 执业证书号：S0010524110003 邮箱： zhengyang@hazq.com 相关报告 1.海风进入项目释放期，光伏组件小 幅涨价 2025-03-03 2. Figure AI 公布新模型，机器人及 AIDC 有望受益 2025-02-24 3.新能源电价政策落地，投资收益预 期锚稳定 2025-02-16 主要观点： 光伏：市场氛围转弱，产业链价格涨势停滞 本周 N 型组件跌价 0.5 分/W，主要系 ...

澳华内镜（ [Table_StockNameRptType] 688212） 公司点评 国内市场受行业影响增速放缓，海外市场增长亮眼 | [Table_Rank] | 投资评级：买入（维持） | | | --- | --- | --- | | 报告日期： | 2025-04-14 | | | [Table_BaseData] 收盘价（元） | | 41.50 | | 近 12 个月最高/最低（元） | 59.00/31.51 | | --- | --- | | 总股本（百万股） | 135 | | 流通股本（百万股） | 135 | | 流通股比例（%） | 100.00 | | 总市值（亿元） | 56 | | 流通市值（亿元） | 56 | [Table_CompanyReport] 相关报告 1.【华安医药】公司点评：澳华内镜 （688212）：收入短期承压，期待 2024Q4 改善 2024-10-29 2.【华安医药】公司点评：澳华内镜 （688212）：2024H1 业绩符合预期， 期待下半年招标恢复 2024-08-26 主要观点： [➢Table_Summary] 事件： 公司发布 2024 ...

澳华内镜（ [Table_StockNameRptType] 688212） 公司点评 国内市场受行业影响增速放缓，海外市场增长亮眼 | [Table_Rank] | 投资评级：买入（维持） | | | --- | --- | --- | | 报告日期： | 2025-04-14 | | | [Table_BaseData] 收盘价（元） | | 41.50 | | 近 12 个月最高/最低（元） | 59.00/31.51 | | --- | --- | | 总股本（百万股） | 135 | | 流通股本（百万股） | 135 | | 流通股比例（%） | 100.00 | | 总市值（亿元） | 56 | | 流通市值（亿元） | 56 | [公司价格与沪深 Table_Chart] 300 走势比较 [Table_Author] 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com 分析师：李婵 执业证书号：S0010523120002 邮箱：lichan@hazq.com [Table_CompanyReport] 相关报告 1.【华安医药】公司点评：澳华内镜 ...

策略研究 周度报告 科技是否迎来主线契机，哪些消费行业尚未轮动？ [Table_RptDate] 报告日期： 2025-04-13 [Table_Author] 分析师：郑小霞 执业证书号：S0010520080007 电话：13391921291 邮箱：zhengxx@hazq.com 分析师：张运智 执业证书号：S0010523070001 电话：13699270398 邮箱：zhangyz@hazq.com 分析师：任思雨 执业证书号：S0010523070003 电话：18501373409 邮箱：rensy@hazq.com 相关报告 1.策略周报《关税加征能否改变市场 结构？—20250406 第 14 周》2025-04- 06 2.策略月报《风起浪动—2025 年 4 月 A 股市场研判及配置机会》2025-03-30 3.策略周报《历年二季度哪些板块容 易出现行情？—20250323 第 12 周》 4.策略周报《消费主线是否迎来机 会？—20250316 第 11 周》 主要观点 分析师：刘超 执业证书号：S0010520090001 电话：13269985073 邮箱：liuchao@h ...

[Table_IndNameRptType] 电子 行业周报 电子行业周报：构建自主可控产业链，关税战的本质是科技战 [Table_IndRank] 行业评级：增持 报告日期：2025-04-13 [Table_Chart] 行业指数与沪深 300 走势比较 -20% -10% 0% 10% 20% 30% 40% 50% 60% 70% 4/24 7/24 10/24 1/25 电子(申万) 沪深300 [Table_Author] 分析师：陈耀波 执业证书号：S0010523060001 邮箱：chenyaobo@hazq.com [Table_Author] 分析师：李美贤 执业证书号：S0010524020002 邮箱：limeixian@hazq.com [Table_Author] 分析师：刘志来 主要观点： ⚫[Table_Summary] 本周行情回顾 从指数表现来看，本周（2025-04-07 至 2025-04-11），上证指数周涨跌- 3.11%，深证成指涨跌幅为-5.13%，创业板指数涨跌幅-6.73%，科创 50 涨跌幅为-0.63%，申万电子指数涨跌幅-3.89%。板块行业指数来看 ...

[Table_IndNameRptType] 电子 行业周报 电子行业周报：构建自主可控产业链，关税战的本质是科技战 [Table_IndRank] 行业评级：增持 报告日期：2025-04-13 [Table_Chart] 行业指数与沪深 300 走势比较 -20% -10% 0% 10% 20% 30% 40% 50% 60% 70% 4/24 7/24 10/24 1/25 电子(申万) 沪深300 [Table_Author] 分析师：陈耀波 执业证书号：S0010523060001 邮箱：chenyaobo@hazq.com [Table_Author] 分析师：李美贤 执业证书号：S0010524020002 邮箱：limeixian@hazq.com [Table_Author] 分析师：刘志来 执业证书号：S0010523120005 邮箱：liuzhilai@hazq.com [Table_Author] 分析师：李元晨 执业证书号：S0010524070001 邮箱：liyc@hazq.com 主要观点： ⚫[Table_Summary] 本周行情回顾 从指数表现来看，本周（2025-04 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.078 billion yuan in 2024, representing a year-on-year growth of 15.70%, while the net profit attributable to shareholders decreased by 3.98% to 177 million yuan. The fourth quarter saw a revenue decline of 32.62% year-on-year, with a net profit of -30 million yuan, down 321.33% [5][7] - New orders continue to grow, with a total of 1.786 billion yuan in new orders signed in 2024, an increase of 18.74% year-on-year, and a cumulative backlog of 3.273 billion yuan, up 27.57% [5] - The company has significantly increased its R&D investment, with R&D expenses reaching 172 million yuan in 2024, a 39.02% increase, accounting for 15.94% of revenue. The company has over 430 R&D projects, with more than 89 new self-research projects initiated [6] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 1.078 billion yuan, with a year-on-year growth of 15.70%. The net profit attributable to shareholders was 177 million yuan, down 3.98%. The fourth quarter revenue was 162 million yuan, a decline of 32.62%, and the net profit was -30 million yuan, a decrease of 321.33% [5][10] Business Segments - The revenue from pharmaceutical research services in 2024 was 559 million yuan, down 1.74%, with a gross margin of 61.37%. The clinical trial and bioanalysis business generated 512 million yuan, up 41.19%, with a gross margin of 31.17%. Revenue from equity sharing was 6.5336 million yuan [5] R&D Investment - The company has increased its R&D expenses to 172 million yuan in 2024, a 39.02% increase, representing 15.94% of total revenue. The company has over 430 R&D projects, with significant progress in clinical trials for various indications [6] Future Projections - Revenue projections for 2025 to 2027 are 1.290 billion yuan, 1.513 billion yuan, and 1.781 billion yuan, with year-on-year growth rates of 19.6%, 17.3%, and 17.7% respectively. Net profit projections for the same period are 213 million yuan, 256 million yuan, and 304 million yuan, with growth rates of 20.3%, 20.0%, and 18.7% respectively [7][10]

Investment Rating - The report maintains a "Buy" rating for the company, indicating expected returns exceeding the market benchmark by more than 15% over the next 6-12 months [8]. Core Views - The company achieved a revenue of 35.14 billion yuan in 2024, representing a year-on-year growth of 9.6%, with a net profit attributable to shareholders of 3.62 billion yuan, up 10.1% year-on-year [5][10]. - The report highlights the company's strategic positioning in the AI wave, leveraging its technology, customer relationships, and production capacity to capitalize on the growing demand in the consumer electronics market [5][6]. - The company is expected to benefit from the increasing penetration of AI features in consumer electronics, with global AI smartphone shipments projected to reach 16% of total smartphone shipments in 2024, growing to 54% by 2028 [6][7]. Financial Performance Summary - In Q4 2024, the company reported a revenue of 11.65 billion yuan, a year-on-year increase of 0.4% and a quarter-on-quarter increase of 12.5% [5]. - The gross margin for Q4 2024 was 21.4%, showing a slight decline compared to previous periods, while total expenses decreased significantly due to positive financial income [5]. - The company forecasts net profits of 4.19 billion yuan, 4.62 billion yuan, and 5.00 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.81 yuan, 1.99 yuan, and 2.16 yuan [8][10].

Investment Rating - The report maintains a "Buy" rating for the company, expecting it to outperform the market benchmark by 5% to 15% over the next 6-12 months [8]. Core Views - The company achieved a revenue of 35.14 billion yuan in 2024, representing a year-on-year growth of 9.6%, with a net profit attributable to shareholders of 3.62 billion yuan, up 10.1% year-on-year [5][10]. - The report highlights the company's strategic positioning in the AI wave, leveraging its technology, customer relationships, and production capacity to capture opportunities in the consumer electronics market [5][6]. - The global economic recovery and domestic policies are expected to drive demand for smartphones and consumer electronics, supporting the company's short-term performance [5]. Financial Performance - In Q4 2024, the company reported a revenue of 11.65 billion yuan, a year-on-year increase of 0.4% and a quarter-on-quarter increase of 12.5% [5]. - The gross margin for Q4 2024 was 21.4%, showing a slight decline compared to previous periods, while total expenses decreased significantly due to positive financial income [5]. - The company forecasts net profits of 4.19 billion yuan, 4.62 billion yuan, and 5.00 billion yuan for 2025, 2026, and 2027 respectively, with corresponding EPS of 1.81 yuan, 1.99 yuan, and 2.16 yuan [8][10]. Market Outlook - The report cites Canalys' prediction that AI smartphone shipments will account for 16% of total smartphone shipments in 2024, increasing to 54% by 2028, with a compound annual growth rate of 63% [6]. - The company is positioned to benefit from the upgrade of 800G/1.6T optical modules and aims to expand its SLP product offerings in the AI sector [7].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 2.93 billion yuan for 2024, representing a year-on-year growth of 15.9%, and a net profit attributable to shareholders of 255 million yuan, a significant increase of 399.7% year-on-year [4][5] - The company is experiencing a decline in quarterly performance, with Q4 2024 revenue at 570 million yuan, down 24.2% year-on-year and 27.8% quarter-on-quarter, attributed to the exit from low-margin products and customer inventory adjustments [5][6] - The gross margin for 2024 improved to 30.4%, up 5.6 percentage points year-on-year, with Q4 2024 gross margin at 33.5%, marking five consecutive quarters of growth [6] - The company is expanding its market presence in consumer electronics, industrial interconnect, and automotive electronics, with a 17% increase in customer numbers and a 45% growth in new markets [6] Financial Summary - For 2024, the company achieved a revenue of 2.93 billion yuan, with a projected revenue growth of 26.6% for 2025 [9] - The net profit attributable to shareholders is expected to reach 400 million yuan in 2025, reflecting a year-on-year growth of 57% [9] - The projected EPS for 2025 is 1.72 yuan per share, with a P/E ratio of 36.6 [7][9] - The company anticipates continued improvement in gross margin, reaching 33.2% in 2025 [9]